MTARC2

Across TCGA pan-cancer cohorts, MTARC2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MTARC2 data layer compared with 22 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MTARC2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MTARC2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where MTARC2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.286	0.892	.006	34	view →
CCRCC	OS	Tertile	All	1.000	0.866	.005	31	view →
PDAC	OS	Median	III,IV	0.567	0.297	.010	13	view →
LUAD	DFS	Quartile	III,IV	0.424	0.996	.040	5	view →
LSCC	DFS	Quartile	II,III,IV	0.633	1.000	.007	4	view →
GBM	DFS	Tertile	All	0.315	0.459	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MTARC2–HNSC (DFS)

Open the HNSC breakdown →